USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Vital Signs - Biomarkers for Improved and Accelerated Sepsis Treatment: Enabling Clinicians to Definitively Diagnose the Disease, Identify the Causative Agent, and Determine the Appropriate Type and Dosage of Antibiotic
Vital Signs - Biomarkers for Improved and Accelerated Sepsis Treatment: Enabling Clinicians to Definitively Diagnose the Disease, Identify the Causative Agent, and Determine the Appropriate Type and Dosage of Antibiotic
RELEASE DATE
23-Aug-2010
23-Aug-2010
REGION
North America
North America
Research Code: 9561-00-AC-00-00
SKU: HC00601-NA-MR_04074
$1,500.00
Special Price $1,125.00 save 25 %
In stock
SKU
HC00601-NA-MR_04074
Description
This issue of Vital Signs, released on August 23, 2010, provides a strategic analysis of trends in biomarkers for improved and accelerated sepsis treatment. Additionally, a company spotlight is provided for B•R•A•H•M•S, a global biotechnology company committed to improving healthcare through the discovery and development of novel and innovative biomarkers for the diagnosis, treatment, and therapeutic management of severe, life-threatening diseases. Reimbursement and regulatory news from the FDA is also provided for the week of July 26, 2010.
Table of Contents
This week's issue:
Popular Topics
This issue of Vital Signs, released on August 23, 2010, provides a strategic analysis of trends in biomarkers for improved and accelerated sepsis treatment. Additionally, a company spotlight is provided for BRAHMS, a global biotechnology company committed to improving healthcare through the discovery and development of novel and innovative biomarkers for the diagnosis, treatment, and therapeutic management of severe, life-threatening diseases. Reimbursement and regulatory news from the FDA is also provided for the week of July 26, 2010.
| No Index | No |
|---|---|
| Podcast | No |
| Industries | Healthcare |
| WIP Number | 9561-00-AC-00-00 |
| Is Prebook | No |